Literature DB >> 12848964

Antiphospholipid syndrome: pathogenic mechanisms.

Gerard Espinosa1, Ricard Cervera, Josep Font, Yehuda Shoenfeld.   

Abstract

Despite the strong association between antiphospholipid antibodies (aPL) and thrombosis, the pathogenic role of aPL in the development of thrombosis has not been fully elucidated. Proposed pathophysiological mechanisms may be categorized into two types. First, aPL may act in vivo by disrupting the kinetics of the normal procoagulant and anticoagulant reactions occurring on cell membranes. Second, aPL may stimulate certain cells thereby altering the expression and secretion of various molecules. In this article, we review the mechanisms by which aPL may develop thrombotic events.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848964     DOI: 10.1016/s1568-9972(02)00144-1

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  11 in total

Review 1.  Potential use of statins in the treatment of antiphospholipid syndrome.

Authors:  Chary Lopez-Pedrera; Patricia Ruiz-Limon; M Angeles Aguirre; Antonio Rodriguez-Ariza; Maria José Cuadrado
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

2.  Catastrophic antiphospholipid syndrome: first signs in the neonatal period.

Authors:  Marta Cabral; Clara Abadesso; Marta Conde; Helena Almeida; Helena Carreiro
Journal:  Eur J Pediatr       Date:  2011-08-16       Impact factor: 3.183

3.  Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy.

Authors:  Swasti Chaturvedi; Leonardo Brandao; Denis Geary; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2011-03-23       Impact factor: 3.714

4.  Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome.

Authors:  Daniel Navarro-Carpentieri; Maria Del Carmen Castillo-Hernandez; Karim Majluf-Cruz; Guillermo Espejo-Godinez; Paola Carmona-Olvera; Manuel Moreno-Hernandez; Yolanda Lugo-García; Jesús Hernandez-Juarez; Luis Loarca-Piña; Irma Isordia-Salas; Abraham Majluf-Cruz
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389

5.  CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexes.

Authors:  A Amirkhosravi; Y Boulaftali; L Robles-Carrillo; T Meyer; S E McKenzie; J L Francis; W Bergmeier
Journal:  J Thromb Haemost       Date:  2014-10-30       Impact factor: 5.824

6.  Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome.

Authors:  V Salle; J C Mazière; A Smail; R Cévallos; C Mazière; V Fuentes; B Tramier; R Makdassi; G Choukroun; O Vittecoq; V Goëb; J P Ducroix
Journal:  J Clin Immunol       Date:  2008-03-06       Impact factor: 8.317

7.  The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation.

Authors:  Christoph Fickentscher; Iryna Magorivska; Christina Janko; Mona Biermann; Rostyslav Bilyy; Cecilia Nalli; Angela Tincani; Veronica Medeghini; Antonella Meini; Falk Nimmerjahn; Georg Schett; Luis E Muñoz; Laura Andreoli; Martin Herrmann
Journal:  J Immunol Res       Date:  2015-06-22       Impact factor: 4.818

8.  Pathogenesis of Antiphospholipid Syndrome.

Authors:  Borut Bo Ic
Journal:  EJIFCC       Date:  2004-08-31

Review 9.  Current concepts in the diagnosis and management of antiphospholipid syndrome and ocular manifestations.

Authors:  Gunay Uludag; Neil Onghanseng; Anh N T Tran; Muhammad Hassan; Muhammad Sohail Halim; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-04-09

10.  A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations.

Authors:  Debbie Jiang; Wendy Lim; Mark Crowther; David Garcia
Journal:  Blood Adv       Date:  2021-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.